Phase I study on the safety and preliminary efficacy of allogeneic mesenchymal stem cells in hypoxic-ischemic encephalopathy

BACKGROUND Hypoxic-ischemic encephalopathy (HIE) is a leading cause of morbidity and mortality in the adult as well as in the neonate, with limited options for treatment and significant dysfunctionality. AIM To investigate the safety and preliminary efficacy of allogeneic mesenchymal stem cells (MSCs) in HIE patients. METHODS Patients who had HIE for at least 6 mo along with significant dysfunction and disability were included. All patients were given Wharton’s jelly-derived MSCs at 1 × 106/kg intrathecally, intravenously, and intramuscularly twice a month for two months. The therapeutic effects and prognostic implications of MSCs were evaluated by multiple follow-ups. Functional independence measure (FIM), modified Ashworth, and Karnofsky scales were used to assess any side effects, neurological and cognitive functions, and overall outcomes. RESULTS The 8 subjects included in the study had a mean age of 33.25 ± 10.18 years. Mean HIE exposure and mean post-HIE durations were 45.63 ± 10.18 and 19.67 ± 29.04 mo, respectively. Mean FIM score was 18.38 ± 1.06, mean modified Ashworth score was 43.5 ± 4.63, and mean Karnofsky score was 20. For the first 24 h, 5 of the patients experienced a subfebrile state, accompanied by mild headaches due to intrathecally administration and muscle pain because of intramuscularly administration. Neurological and functional examinations, laboratory tests, electroencephalography, and magnetic resonance imaging were performed to assess safety of treatment. Mean FIM score increased by 20.88 ± 3.31 in the first month (P = 0.027) and by 31.38 ± 14.69 in 12 mo (P = 0.012). The rate of patients with an FIM score of 126 increased from 14.58% to 16.57% in the first month and 24.90% in 12 mo. CONCLUSION Multiple triple-route Wharton’s jelly-derived MSC administrations were found to be safe for HIE patients, indicating neurological and functional improvement. Based on the findings obtained here, further randomized and placebo research could be performed.

[1]  Tingting Yang,et al.  Efficacy of different treatment times of mild cerebral hypothermia on oxidative factors and neuroprotective effects in neonatal patients with moderate/severe hypoxic–ischemic encephalopathy , 2020, The Journal of international medical research.

[2]  D. Curran,et al.  Neurocognitive outcomes in adults following cerebral hypoxia: A systematic literature review. , 2020, NeuroRehabilitation.

[3]  Clémence Disdier,et al.  Hypoxic-ischemic related cerebrovascular changes and potential therapeutic strategies in the neonatal brain , 2019, Journal of neuroscience research.

[4]  G. Besner,et al.  Stem Cell Therapy for Preventing Neonatal Diseases in the 21st Century: Current Understanding and Challenges , 2019, Pediatric Research.

[5]  X. Xiong,et al.  Mechanism and Treatment Related to Oxidative Stress in Neonatal Hypoxic-Ischemic Encephalopathy , 2019, Front. Mol. Neurosci..

[6]  Lubo Zhang,et al.  Neural stem cell therapies and hypoxic-ischemic brain injury , 2019, Progress in Neurobiology.

[7]  E. Karaöz,et al.  Wharton’s Jelly-Derived Mesenchymal Stem Cell Transplantation in a Patient with Hypoxic-Ischemic Encephalopathy , 2018, Cell transplantation.

[8]  S. Erdoğan,et al.  The Effect of Umbilical Cord-derived Mesenchymal Stem Cell Transplantation in a Patient with Cerebral Palsy: A Case Report , 2018, International journal of stem cells.

[9]  M. Dimitrijevic,et al.  Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017) , 2018, Cell transplantation.

[10]  Luzhe Sun,et al.  Therapeutic potential of mesenchymal stromal cells for hypoxic ischemic encephalopathy: A systematic review and meta-analysis of preclinical studies , 2017, PloS one.

[11]  S. Kumaran,et al.  Safety and Feasibility of Autologous Mesenchymal Stem Cell Transplantation in Chronic Stroke in Indian patients. A four-year follow up , 2017, Journal of stem cells & regenerative medicine.

[12]  Jee-Yin Ahn,et al.  Mesenchymal Stem Cells: The Magic Cure for Intraventricular Hemorrhage? , 2017, Cell transplantation.

[13]  Martin Mueller,et al.  Mesenchymal Stem Cells from Wharton's Jelly and Amniotic Fluid. , 2016, Best practice & research. Clinical obstetrics & gynaecology.

[14]  Xiaoying Wu,et al.  Umbilical cord mesenchymal stem cells in neurological disorders: A clinical study. , 2015, Indian journal of biochemistry & biophysics.

[15]  Ling Wei,et al.  Cell based therapies for ischemic stroke: From basic science to bedside , 2014, Progress in Neurobiology.

[16]  H. van Loveren,et al.  An Update on Translating Stem Cell Therapy for Stroke from Bench to Bedside , 2013, Journal of clinical medicine.

[17]  M. Chopp,et al.  Different routes of administration of human umbilical tissue-derived cells improve functional recovery in the rat after focal cerebral ischemia , 2012, Brain Research.

[18]  D. Brandon,et al.  Hypoxic Ischemic Encephalopathy: Pathophysiology and Experimental Treatments. , 2011, Newborn and infant nursing reviews : NAINR.

[19]  E. Wróbel,et al.  Perinatal sources of mesenchymal stem cells: Wharton’s jelly, amnion and chorion , 2011, Cellular & Molecular Biology Letters.

[20]  S. Gambardella,et al.  Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art. , 2010, International journal of clinical and experimental medicine.

[21]  Yuanlin Liu,et al.  Identification of mesenchymal stem cells in aorta-gonad-mesonephros and yolk sac of human embryos. , 2008, Blood.

[22]  F. Claas,et al.  Isolation of Mesenchymal Stem Cells of Fetal or Maternal Origin from Human Placenta , 2004, Stem cells.

[23]  J. Reneker,et al.  Outcome Measure Scores Predict Discharge Destination in Patients With Acute and Subacute Stroke: A Systematic Review and Series of Meta-analyses , 2018, Journal of neurologic physical therapy : JNPT.

[24]  H. Shintaku,et al.  Future perspectives of cell therapy for neonatal hypoxic–ischemic encephalopathy , 2018, Pediatric Research.

[25]  R. Sidman,et al.  Functional Multipotency of Neural Stem Cells and Its Therapeutic Implications , 2010 .